We undertook this 32-week , open-label , phase 3 non-inferiority study at 162 sites in eight countries : USA ( 121 sites ) , Australia ( 9 sites ) , Peru ( 7 sites ) , Philippines ( 7 sites ) , South Korea ( 5 sites ) , UK ( 5 sites ) , Israel ( 4 sites ) , and Spain ( 4 sites ) .